Adrian van den Hoven has been director general of Medicines for Europe since September 2013. In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries. He is also member of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the International Generic and Biosimilar medicines Association (IGBA) and the joint industry advisory council of the Health Emergency and Response Authority (HERA).
